Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide
2. 2-2etn-2mephacn
3. Dalcaine
4. Lidocaine
5. Lidocaine Carbonate
6. Lidocaine Carbonate (2:1)
7. Lidocaine Hydrocarbonate
8. Lidocaine Monoacetate
9. Lidocaine Monohydrochloride
10. Lidocaine Monohydrochloride, Monohydrate
11. Lidocaine Sulfate (1:1)
12. Octocaine
13. Xylesthesin
14. Xylocaine
15. Xylocitin
16. Xyloneural
1. 73-78-9
2. Lidocaine Hcl
3. Lidothesin
4. Xyloneural
5. Lignocaine Hydrochloride
6. Lidocaine (hydrochloride)
7. Lidocaton
8. Xylocard
9. Lidocaine Hydrochloride Anhydrous
10. Lidopen
11. Acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, Monohydrochloride
12. Lta Ii Kit
13. Laryng-o-jet Kit
14. Ec2cnf7xfp
15. Linocaine Hydrochloride
16. Mls000069665
17. Laryngotracheal Anesthesia Kit
18. 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide Hydrochloride
19. 2-diethylamino-2',6'-acetoxylidide Hydrochloride
20. Alphacaine Hydrochloride
21. Nsc-757420
22. Smr000058468
23. Xylocaine (tn)
24. Alpha-diethylamino-2,6-acetoxylidine Hydrochloride
25. Laryng-o-jet
26. Omega-diethylamino-2,6-dimethylacetanilide Hydrochloride
27. Xilina Hydrochloride
28. 73-78-9 (hcl); 6108-05-0 (monohydrate)
29. Rucaina Hydrochloride
30. Xycaine Hydrochloride
31. Xylotox Hydrochloride
32. Duncaine Hydrochloride
33. Isicaine Hydrochloride
34. Lidocain Hydrochloride
35. Anestacon Hydrochloride
36. Gravocain Hydrochloride
37. Leostesin Hydrochloride
38. Xylocitin Hydrochloride
39. Lidothesin Hydrochloride
40. Xylestesin Hydrochloride
41. Glydo
42. Lidocaine Viscous
43. Pediatric Lta Kit
44. Chebi:50512
45. Xylocaine Preservative Free
46. Sr-01000000189
47. Unii-ec2cnf7xfp
48. Einecs 200-803-8
49. Xylocaine 4% Preservative Free
50. Xylocaine 5% W/ Glucose 7.5%
51. Lidocaine Hydrochloride Viscous
52. S 202
53. V 262
54. Xylocaine 1.5% W/ Dextrose 7.5%
55. Dalcaine (tn)
56. Prestwick_296
57. N-(diethylaminoacetyl)-2,6-dimethylaniline Hydrochloride
58. Lidoca Ne Hydrochloride
59. Lidocaine Hydrochloride Preservative Free
60. Opera_id_351
61. Lidocaine Hydrochloride In Plastic Container
62. Lidocaine Hydrochloride 0.2% In Dextrose 5%
63. Lidocaine Hydrochloride 0.4% In Dextrose 5%
64. Lidocaine Hydrochloride 5% And Dextrose 7.5%
65. Spectrum1500689
66. Chembl541521
67. Dtxsid4058782
68. Hy-b0185a
69. 2',6'-acetoxylidide, 2-(diethylamino)-, Monohydrochloride
70. Hms1568i21
71. Hms1921c22
72. Lidocaine Hydrochloride Preservative Free In Plastic Container
73. Pharmakon1600-01500689
74. Lidocaine Hydrochloride (jan/usp)
75. 2',6'-acetoxylidide, 2-(diethylamino)-, Hydrochloride
76. Bcp30473
77. Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container
78. Lidocaine Hydrochloride 0.4% In Dextrose 5% In Plastic Container
79. Lidocaine Hydrochloride 0.8% In Dextrose 5% In Plastic Container
80. Tox21_500669
81. Ccg-39281
82. Lidocaine Hydrochloride [jan]
83. Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
84. Lidocaine Hydrochloride 0.2% And Dextrose 5% In Plastic Container
85. Lidocaine Hydrochloride 0.4% And Dextrose 5% In Plastic Container
86. Lidocaine Hydrochloride 0.8% And Dextrose 5% In Plastic Container
87. Nsc757420
88. S4667
89. (unlabeled)lidocaine-d6 Hydrochloride
90. Akos015889456
91. Cs-3888
92. Lp00669
93. Nsc 757420
94. Sb19119
95. Anhydrous Lidocaine Hydrochloride
96. Lidocaine Hydrochloride [who-dd]
97. Ncgc00094030-01
98. Ncgc00094030-02
99. Ncgc00094030-03
100. Ncgc00094030-04
101. Ncgc00094030-05
102. Ncgc00261354-01
103. Ac-11712
104. As-35171
105. Eu-0100669
106. Lignocaine Hydrochloride Pound>>lidocaine Hcl
107. A16132
108. D02086
109. L 5647
110. Lidocaine Hydrochloride Anhydrous [mart.]
111. A837924
112. Q-201304
113. Sr-01000000189-3
114. Sr-01000000189-9
115. Q27122094
116. 2-(diethylamino)-2',6'-acetoxylidide Monohydrochloride
117. 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;hydrochloride
118. 2-(diethylamino)-n-(2,6-dimethylphenyl)ethanamide Hydrochloride
119. Acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, Hydrochloride (1:1)
| Molecular Weight | 270.80 g/mol |
|---|---|
| Molecular Formula | C14H23ClN2O |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 270.1498911 g/mol |
| Monoisotopic Mass | 270.1498911 g/mol |
| Topological Polar Surface Area | 32.3 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 228 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 18 | |
|---|---|
| Drug Name | Laryng-o-jet kit |
| Drug Label | DESCRIPTIONLidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains a local anesthetic agent and is administered topically. Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains lidocaine hydrochloride, which is che... |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 4% |
| Market Status | Prescription |
| Company | Intl Medication |
| 2 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Jelly; Injectable; Solution |
| Route | Injection; Oral; Topical |
| Strength | 0.5%; 1%; 20%; 2%; 4% |
| Market Status | Prescription |
| Company | Wockhardt; Igi Labs; Hospira; Roxane; Watson Labs; Intl Medication; Hi Tech Pharma; Vintage; Luitpold; Agila Speclts; Akorn |
| 3 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride in plastic container |
| Drug Label | Each mL contains:Lidocaine Hydrochloride . . . . . . . . . . 20 mg (2%)Inactive ingredients: flavoring, methylparaben, propylparaben, sodium carboxymethylcellulose, and sodium saccharin in an aqueous solution.Lidocaine Viscous (Lidocaine Hydrochlorid... |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 0.5%; 1%; 2% |
| Market Status | Prescription |
| Company | Hospira; Fresenius Kabi Usa |
| 4 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride preservative free |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1%; 20%; 1.5%; 2%; 4% |
| Market Status | Prescription |
| Company | Hospira; Aurobindo Pharma; Intl Medication; Fresenius Kabi Usa; Agila Speclts |
| 5 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride preservative free in plastic container |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1%; 2% |
| Market Status | Prescription |
| Company | Hospira |
| 6 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride viscous |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Oral |
| Strength | 2% |
| Market Status | Prescription |
| Company | Vintage |
| 7 of 18 | |
|---|---|
| Drug Name | Lidocaine viscous |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Oral |
| Strength | 2% |
| Market Status | Prescription |
| Company | Roxane |
| 8 of 18 | |
|---|---|
| Drug Name | Lta ii kit |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 4% |
| Market Status | Prescription |
| Company | Hospira |
| 9 of 18 | |
|---|---|
| Drug Name | Xylocaine preservative free |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1%; 20%; 2%; 4% |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 10 of 18 | |
|---|---|
| Drug Name | Laryng-o-jet kit |
| Drug Label | DESCRIPTIONLidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains a local anesthetic agent and is administered topically. Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains lidocaine hydrochloride, which is che... |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 4% |
| Market Status | Prescription |
| Company | Intl Medication |
| 11 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Jelly; Injectable; Solution |
| Route | Injection; Oral; Topical |
| Strength | 0.5%; 1%; 20%; 2%; 4% |
| Market Status | Prescription |
| Company | Wockhardt; Igi Labs; Hospira; Roxane; Watson Labs; Intl Medication; Hi Tech Pharma; Vintage; Luitpold; Agila Speclts; Akorn |
| 12 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride in plastic container |
| Drug Label | Each mL contains:Lidocaine Hydrochloride . . . . . . . . . . 20 mg (2%)Inactive ingredients: flavoring, methylparaben, propylparaben, sodium carboxymethylcellulose, and sodium saccharin in an aqueous solution.Lidocaine Viscous (Lidocaine Hydrochlorid... |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 0.5%; 1%; 2% |
| Market Status | Prescription |
| Company | Hospira; Fresenius Kabi Usa |
| 13 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride preservative free |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1%; 20%; 1.5%; 2%; 4% |
| Market Status | Prescription |
| Company | Hospira; Aurobindo Pharma; Intl Medication; Fresenius Kabi Usa; Agila Speclts |
| 14 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride preservative free in plastic container |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1%; 2% |
| Market Status | Prescription |
| Company | Hospira |
| 15 of 18 | |
|---|---|
| Drug Name | Lidocaine hydrochloride viscous |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Oral |
| Strength | 2% |
| Market Status | Prescription |
| Company | Vintage |
| 16 of 18 | |
|---|---|
| Drug Name | Lidocaine viscous |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Oral |
| Strength | 2% |
| Market Status | Prescription |
| Company | Roxane |
| 17 of 18 | |
|---|---|
| Drug Name | Lta ii kit |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 4% |
| Market Status | Prescription |
| Company | Hospira |
| 18 of 18 | |
|---|---|
| Drug Name | Xylocaine preservative free |
| Active Ingredient | Lidocaine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1%; 20%; 2%; 4% |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Anesthetics, Local
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 4%
USFDA APPLICATION NUMBER - 10417
DOSAGE - INJECTABLE;INJECTION - 1% **Federal ...DOSAGE - INJECTABLE;INJECTION - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 16801
DOSAGE - INJECTABLE;INJECTION - 2% **Federal ...DOSAGE - INJECTABLE;INJECTION - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 16801
DOSAGE - INJECTABLE;INJECTION - 20% **Federal...DOSAGE - INJECTABLE;INJECTION - 20% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 16801
DOSAGE - INJECTABLE;INJECTION - 4% **Federal ...DOSAGE - INJECTABLE;INJECTION - 4% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 16801
DOSAGE - INJECTABLE;INJECTION - 0.005MG/ML;0....DOSAGE - INJECTABLE;INJECTION - 0.005MG/ML;0.5%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.005MG/ML;1%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.005MG/ML;1....DOSAGE - INJECTABLE;INJECTION - 0.005MG/ML;1.5%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.005MG/ML;2%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.01MG/ML;1%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.01MG/ML;2%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.02MG/ML;2%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 0.5%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 1%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 1.5%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 2%
USFDA APPLICATION NUMBER - 6488
DOSAGE - INJECTABLE;INJECTION - 1%
USFDA APPLICATION NUMBER - 83158
DOSAGE - INJECTABLE;INJECTION - 2%
USFDA APPLICATION NUMBER - 83158
DOSAGE - INJECTABLE;INJECTION - 1%
USFDA APPLICATION NUMBER - 83173
DOSAGE - INJECTABLE;SPINAL - 5%
USFDA APPLICATION NUMBER - 83914
DOSAGE - JELLY;TOPICAL - 2% **Federal Registe...DOSAGE - JELLY;TOPICAL - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 8816
DOSAGE - INJECTABLE;INJECTION - EQ 0.02MG BAS...DOSAGE - INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%
USFDA APPLICATION NUMBER - 88389
DOSAGE - INJECTABLE;INJECTION - EQ 0.01MG BAS...DOSAGE - INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%
USFDA APPLICATION NUMBER - 88390
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]PMC Isochem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Capital Farma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]BioSpectra
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Doshion Polyscience
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nippon Fine Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shandong Focus Biotechnology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Symrise
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Coating Systems & Additives
Thickeners and Stabilizers
Fillers, Diluents & Binders
Parenteral
Controlled & Modified Release
Emulsifying Agents
Film Formers & Plasticizers
Surfactant & Foaming Agents
Rheology Modifiers
Granulation
Taste Masking
Direct Compression
Co-Processed Excipients
API Stability Enhancers
Lubricants & Glidants
Chewable & Orodispersible Aids
Disintegrants & Superdisintegrants
Empty Capsules
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
98
PharmaCompass offers a list of Lidocaine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lidocaine Hydrochloride manufacturer or Lidocaine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lidocaine Hydrochloride manufacturer or Lidocaine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Lidocaine Hydrochloride API Price utilized in the formulation of products. Lidocaine Hydrochloride API Price is not always fixed or binding as the Lidocaine Hydrochloride Price is obtained through a variety of data sources. The Lidocaine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LIGNOSPAN FORTE-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LIGNOSPAN FORTE-1, including repackagers and relabelers. The FDA regulates LIGNOSPAN FORTE-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LIGNOSPAN FORTE-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of LIGNOSPAN FORTE-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A LIGNOSPAN FORTE-1 supplier is an individual or a company that provides LIGNOSPAN FORTE-1 active pharmaceutical ingredient (API) or LIGNOSPAN FORTE-1 finished formulations upon request. The LIGNOSPAN FORTE-1 suppliers may include LIGNOSPAN FORTE-1 API manufacturers, exporters, distributors and traders.
click here to find a list of LIGNOSPAN FORTE-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LIGNOSPAN FORTE-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of LIGNOSPAN FORTE-1 active pharmaceutical ingredient (API) in detail. Different forms of LIGNOSPAN FORTE-1 DMFs exist exist since differing nations have different regulations, such as LIGNOSPAN FORTE-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LIGNOSPAN FORTE-1 DMF submitted to regulatory agencies in the US is known as a USDMF. LIGNOSPAN FORTE-1 USDMF includes data on LIGNOSPAN FORTE-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LIGNOSPAN FORTE-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LIGNOSPAN FORTE-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The LIGNOSPAN FORTE-1 Drug Master File in Japan (LIGNOSPAN FORTE-1 JDMF) empowers LIGNOSPAN FORTE-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the LIGNOSPAN FORTE-1 JDMF during the approval evaluation for pharmaceutical products. At the time of LIGNOSPAN FORTE-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of LIGNOSPAN FORTE-1 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a LIGNOSPAN FORTE-1 Drug Master File in Korea (LIGNOSPAN FORTE-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of LIGNOSPAN FORTE-1. The MFDS reviews the LIGNOSPAN FORTE-1 KDMF as part of the drug registration process and uses the information provided in the LIGNOSPAN FORTE-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a LIGNOSPAN FORTE-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their LIGNOSPAN FORTE-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of LIGNOSPAN FORTE-1 suppliers with KDMF on PharmaCompass.
A LIGNOSPAN FORTE-1 CEP of the European Pharmacopoeia monograph is often referred to as a LIGNOSPAN FORTE-1 Certificate of Suitability (COS). The purpose of a LIGNOSPAN FORTE-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of LIGNOSPAN FORTE-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of LIGNOSPAN FORTE-1 to their clients by showing that a LIGNOSPAN FORTE-1 CEP has been issued for it. The manufacturer submits a LIGNOSPAN FORTE-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a LIGNOSPAN FORTE-1 CEP holder for the record. Additionally, the data presented in the LIGNOSPAN FORTE-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the LIGNOSPAN FORTE-1 DMF.
A LIGNOSPAN FORTE-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. LIGNOSPAN FORTE-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of LIGNOSPAN FORTE-1 suppliers with CEP (COS) on PharmaCompass.
A LIGNOSPAN FORTE-1 written confirmation (LIGNOSPAN FORTE-1 WC) is an official document issued by a regulatory agency to a LIGNOSPAN FORTE-1 manufacturer, verifying that the manufacturing facility of a LIGNOSPAN FORTE-1 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting LIGNOSPAN FORTE-1 APIs or LIGNOSPAN FORTE-1 finished pharmaceutical products to another nation, regulatory agencies frequently require a LIGNOSPAN FORTE-1 WC (written confirmation) as part of the regulatory process.
click here to find a list of LIGNOSPAN FORTE-1 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing LIGNOSPAN FORTE-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for LIGNOSPAN FORTE-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture LIGNOSPAN FORTE-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain LIGNOSPAN FORTE-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a LIGNOSPAN FORTE-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of LIGNOSPAN FORTE-1 suppliers with NDC on PharmaCompass.
LIGNOSPAN FORTE-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LIGNOSPAN FORTE-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LIGNOSPAN FORTE-1 GMP manufacturer or LIGNOSPAN FORTE-1 GMP API supplier for your needs.
A LIGNOSPAN FORTE-1 CoA (Certificate of Analysis) is a formal document that attests to LIGNOSPAN FORTE-1's compliance with LIGNOSPAN FORTE-1 specifications and serves as a tool for batch-level quality control.
LIGNOSPAN FORTE-1 CoA mostly includes findings from lab analyses of a specific batch. For each LIGNOSPAN FORTE-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LIGNOSPAN FORTE-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (LIGNOSPAN FORTE-1 EP), LIGNOSPAN FORTE-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LIGNOSPAN FORTE-1 USP).
